Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carmell Therapeutics Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on Aesthetics","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV"},{"orgOrder":0,"company":"Axolotl Biologix","sponsor":"Carmell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative Medicine","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV"}]

    Find Clinical Drug Pipeline Developments & Deals by Axolotl Biologix

    Menu

    Axolotl Biologix

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Axolotl Biologix

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Moonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative Medicine

              Details:

              Axolotl designs, develops and sells human amnion-based allograft products for active soft tissue repair, aesthetics and orthopedic indications and is also enrolling a Phase I/II trial for Ankle Osteoarthritis and developing a topical cosmeceutical for skin rejuvenation.

              Lead Product(s): Axolotl Graft

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Axolotl Graft

              Highest Development Status: Phase IV Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Carmell Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger September 12, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Axolotl Biologix

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Carmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on Aesthetics

              Details:

              Axolotl designs, develops and sells human amnion-based allograft products for active soft tissue repair, aesthetics and orthopedic indications and is also enrolling a Phase I/II trial for Ankle Osteoarthritis and developing a topical cosmeceutical for skin rejuvenation.

              Lead Product(s): Axolotl Graft

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Axolotl Graft

              Highest Development Status: Phase IV Product Type: Large molecule

              Partner/Sponsor/Collaborator: Carmell Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger September 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Axolotl Biologix

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity

              Details:

              Axolotl designs, develops and sells human amnion-based allograft products for active soft tissue repair, aesthetics and orthopedic indications and is also enrolling a Phase I/II trial for Ankle Osteoarthritis and developing a topical cosmeceutical for skin rejuvenation.

              Lead Product(s): Axolotl Graft

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Axolotl Graft

              Highest Development Status: Phase IV Product Type: Large molecule

              Partner/Sponsor/Collaborator: Carmell Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger August 09, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Axolotl Biologix

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Carmell Therapeutics Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company

              Details:

              Axolotl designs, develops and sells human amnion-based allograft products for active soft tissue repair, aesthetics and orthopedic indications and is also enrolling a Phase I/II trial for Ankle Osteoarthritis and developing a topical cosmeceutical for skin rejuvenation.

              Lead Product(s): Axolotl Graft

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Axolotl Graft

              Highest Development Status: Phase IV Product Type: Large molecule

              Partner/Sponsor/Collaborator: Carmell Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger July 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY